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Introduction: Mesenchymal stromal/stem cells (MSCs) for clinical use have largely been isolated from the bone
marrow, although isolation of these cells from many different adult and fetal tissues has been reported as well. One
such source of MSCs is the Whartons Jelly (WJ) of the umbilical cord, as it provides an inexhaustible source of stem
cells for potential therapeutic use. Isolation of MSCs from the umbilical cord also presents little, if any, ethical
concerns, and the process of obtaining the cord tissue is relatively simple with appropriate consent from the donor.
However, a great majority of studies rely on the use of bovine serum containing medium for isolation and
expansion of these cells, and porcine derived trypsin for dissociating the cells during passages, which may pose
potential risks for using these cells in clinical applications. It is therefore of high priority to develop a robust
production process by optimizing culture variables to efficiently and consistently generate MSCs that retain desired
regenerative and differentiation properties while minimizing risk of disease transmission.
Methods: We have established a complete xeno-free, serum-free culture condition for isolation, expansion and
characterization of WJ-MSCs, to eliminate the use of animal components right from initiation of explant culture to
clinical scale expansion and cryopreservation. Growth kinetics, in vitro differentiation capacities, immunosuppressive
potential and immunophenotypic characterization of the cells expanded in serum-free media have been compared
against those cultured under standard fetal bovine serum (FBS) containing medium. We have also compared
the colony-forming frequency and genomic stability of the large scale expanded cells. Secretome analysis was
performed to compare the angiogenic cytokines and functional angiogenic potency was proved by Matrigel assays.
Results: Results presented in this report identify one such serum-free, xeno-free medium for WJ expansion. Cells
cultured in serum-free, xeno-free medium exhibit superior growth kinetics and functional angiogenesis, alongside
other MSC characteristics.
Conclusions: We report here that WJ-MSCs cultured and expanded in Mesencult XF, SF Medium retain all necessary
characteristics attributed to MSC for potential therapeutic use.* Correspondence: sudha.b@stempeutics.com
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Mesenchymal stem cells (MSCs), also known as multi-
potent stromal cells or mesenchymal progenitor cells
(MPCs), have gained attention in regenerative medicine
and tissue engineering applications ultimately leading to
potential tissue repair due to their regenerative capabil-
ity, multilineage differentiation potential and immuno-
modulatory activity [1-4]. MSCs were originally isolated
and characterized from bone marrow (BM) [5], but sub-
sequently have been derived from almost all postnatal
tissues, such as adipose, dental pulp, umbilical cord and
cord blood, amniotic fluid, limbal tissue and so on [6-8].
Clinical studies employing human MSCs from different
sources have been initiated for treatment of several dis-
eases, such as graft-versus host disease (GvHD), cartilage
regeneration, myocardial infarction, diabetes, peripheral
arterial disease and so on (http://clinicaltrials.gov/).
Although BM is the traditional and the most well
characterized source of human MSCs, it has certain li-
mitations, such as subjecting the donors to painful iso-
lation, decline in MSC precursor frequency with age,
reduced proliferation capacity and non-optimal differen-
tiation potential of these cells. When compared against
other tissues, the umbilical cord appears to provide an
inexhaustible source of stem cells for therapy and use of
this tissue would not involve invasive procedures or eth-
ical concerns. MSCs have been isolated from different
compartments of the umbilical cord; Wharton’s Jelly
(WJ) is the embryonic mucous connective tissue lying
between the amniotic epithelium and the umbilical ves-
sels and is a rich source of MSCs [9-11]. WJ-MSCs share
some properties unique to fetal-derived MSCs, such as
faster proliferation and greater ex vivo expansion cap-
abilities, compared to adult MSCs [12].
Most of the MSC expansion procedures involve the
use of bovine serum containing medium for culturing
the cells and porcine derived trypsin for dissociating the
cells and the use of these two ingredients poses a poten-
tial risk of transmitting unknown viruses, mycoplasma,
prions or unidentified zoonotic agents. Moreover, the
presence of a high quantity of xenogeneic proteins can
cause concerns related to immune reactions in human
patients [13]. Also, a high degree of batch-to-batch vari-
ation could cause inconsistency in generating quality-
controlled cells, thus making standardization of the
production process difficult. Although the use of ani-
mal serum for cell expansion is not prohibited, the
development of serum substitutes and xeno-free and
serum-free medium for MSC has become a high pri-
ority for these reasons. In general, the current proto-
cols for clinical grade production involve isolation of
a small fraction of primary MSCs from the selected
tissue source and expanding them through multiple pas-
sages, in order to generate clinically useful numbers ofcells. Subsequently, these cells are used for the intended
clinical applications [14]. Several cell culture variables,
such as medium formulation (basal media and supple-
ments), cell surface attachment substrate and cell seeding
density at various passages, are critical when developing a
potential cell therapy based product. Keeping these points
in mind, we have compared two commercially avail-
able xeno-free and serum-free media, StemPro XF, SFM
(Invitrogen, Carlsbad, CA, USA) and MesenCult XF, SFM
(Stem Cell Technologies, Vancouver, British Columbia,
Canada), to establish and expand WJ-MSCs. While an
earlier study by Corotchi et al., [15] demonstrated the
isolation and culture of WJ-MSCs in MesenCult me-
dium and their endothelial differentiation propensity,
we have optimized the culture conditions of WJ-MSCs in
Mesencult for large scale expansion and performed exten-
sive characterization based on the requirements of using
these cells in clinical trials. In addition, we have also elimi-
nated the use of animal components right from the isola-
tion step to the clinical scale expansion process. These
WJ-MSCs have been characterized with respect to their
growth kinetics, in vitro differentiation capacity, immuno-
suppressive potential and immunophenotypic analysis.
Our study presents the superiority of the cells cultured in
xeno-free, serum-free conditions when compared against
those grown and expanded under conventional fetal bo-
vine serum (FBS) culture conditions. These results suggest
that the expanded WJ-MSCs met all necessary regulatory
criteria in order to evaluate their therapeutic potential in
pre-clinical and clinical studies.
Methods
MSC isolation and cell culture
Fresh human umbilical cords (n = 10) were obtained after
full-term births (cesarean section or normal vaginal delivery)
with written informed consent using the guidelines ap-
proved by the Institutional Committee for Stem Cell Re-
search and Therapy (ICSCRT) and the Institutional Ethics
Committee (IEC) at the Manipal Hospital, Bangalore, India.
The study was also approved by both the committees.
Briefly, after rinsing with normal saline (0.9% w/v
sodium chloride), the cords were given a quick rinse with
70% isopropyl alcohol (IPA), followed by three washes
with sterile PBS. The umbilical cord vessels were then
removed manually from cord segments, and the exposed
mesenchymal tissue was cut into very small pieces or
explants, approximately 1 to 2 mm, before placing them
in a tissue culture dish. The explants were cultured in:
1) DMEM KO (Cat.no. 10829018, Invitrogen, Carlsbad,
CA, USA) and 2 mM L-glutamine (Cat.no., 25030, Invitro-
gen), supplemented with 10% FBS Cat.no.SH30084.03, Lot
no.GRH0054 (Hyclone, Waltham, MA, USA);
2) MesenCult XF Medium (Cat.no. 05429, Stem Cell
Technologies, Vancouver, British Columbia, Canada),
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Invitrogen); prior to plating, culture dishes were coated
with MesenCult XF Attachment Substrate (Cat.no.
05424, Stem Cell Technologies);
3) StemPro XF, SF media (Cat.no. A10675, Invitrogen),
supplemented with 200 mM L-glutamine (Cat.no. 25030,
Invitrogen); prior to plating, culture dishes were coated
with CELLstart CTS Attachment Substrate (Cat.no.
A1014201, Invitrogen) according to the manufacturers’
protocols.
For subculturing, 0.05% trypsin-ethylenediaminetetraace-
tic acid (EDTA) (Gibco, Life Technologies - Carlsbad, CA,
USA, cat.no. 25300-054) was used for the FBS cultures,
while TryplE Select 10X (Gibco, cat.no. A12177-01) was
used for the XF, SFM cultures. WJ-MSCs were expanded in
culture up to passage 5 to study their growth kinetics. Rep-
resentative pictures were captured at 10 X to compare
morphology of the cells. Mean population doubling, cumu-
lative population doubling and total cell yield were calcu-
lated and compared between the two culture conditions.
Colony forming unit-fibroblast assay
To test the colony forming capacity of the MSCs, the
cells were plated at a density of 100 cells per 35 mm
dish. The cells were incubated for eight days, at which
point they were fixed and stained with 0.1% toluidene
blue in 1% paraformaldehyde (all reagents from Sigma-
Aldrich, St. Louis, MO, USA), to visualize the colonies.
Stained colonies were manually counted. The assay for
each sample was carried out in triplicate.
Immunophenotyping
In order to screen for the presence of MSC positive and
negative markers and to confirm the absence of co-
stimulatory molecules, cells at Passage 3 and Passage 5,
cultured in all three conditions were subjected to flowTable 1 Antibodies used for flow cytometry analysis
Antibody Fluorochrome Catalogue number Sto
CD73 PE 550257, BD
CD44 PE 550989, BD
CD166 PE 559263, BD
CD90 PE 555596, BD
CD105 FITC FAB10971F, R&D
CD200 PE 552475, BD
HLA ABC APC 555555, BD
CD34 PE 550761, BD
CD271 PE 557196, BD
CD80 PE 340294, BD
CD45 FITC 555482, BD
HLA DR FITC 347663, BD
APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.cytometry analysis. The samples were incubated with the
below mentioned antibodies for half an hour at room
temperature, following which the samples were analyzed
using the FACS DIVA and WinMDI 2.9 software. The
expression levels of CD 73, CD 105, CD 44, CD 166, CD
90, HLA ABC, CD 34, CD 45, HLA DR, CD 40, CD 80
and CD 86 were analyzed. The details and concentra-
tions of the antibodies used are given in Table 1.
RT-PCR analysis
Total cellular RNA was isolated using an RNeasy mini
kit (Qiagen, Venlo, Limburg, Netherlands). The RNA
samples were treated with DNA-free DNase I (Ambion,
Life Technologies - Carlsbad, CA, USA), according to
the manufacturer’s instructions and reverse-transcribed
into cDNA using a high capacity cDNA reverse
transcription kit (Applied Biosystems, Life Technologies -
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. Transcripts were amplified using gene specific
primers, for which the primer sequences are provided in
Table 2. A reverse transcriptase negative blank of each
sample and a no template blank served as negative con-
trols. Gene expression was normalized to the housekeep-
ing gene beta actin, used as an internal standard.
Tri-lineage differentiation and quatification
Tri-lineage differentiation of WJ-MSCs into adipocytes,
osteocytes and chondrocytes was carried out using pre-
viously described techniques [10].
Adipogenic differentiation was initiated in confluent cul-
tures of MSCs using complete medium supplemented with
200 mM indomethacin, 0.5 mM 3-isobutyl-1-methylxan-
thine, 10 mg/ml insulin and 1 mM dexamethasone (all re-
agents from Sigma-Aldrich). After 18 days, adipogenic
differentiation was detected by staining the lipid droplets
with Oil Red O (Sigma-Aldrich). For quantitation of lipidck concentraton Antibody dilution Isotype dilution
12.5 μg/ml NEAT 1:16 ISO PE
12.5 μg/ml NEAT 1:16 ISO PE
12.5 μg/ml NEAT 1:16 ISO PE
0.2 mg/ml NEAT NEAT ISO PE
50 μg/ml NEAT 1:10 ISO FITC
0.25 μg/20 ml NEAT NEAT ISO PE
3 μg/ml NEAT 1:4 ISO APC
12.5 μg/ml NEAT 1:16 ISO PE
0.125 μg/20 ml NEAT NEAT ISO PE
0.0032 mg/ml NEAT 1:62.5 ISO PE
6.25 μg/ml NEAT 1:80 ISO FITC
25 μg/ml NEAT 1:2 ISO FITC
Table 2 List of primers used for RT-PCR analysis
Markers Forward primer Reverse primer Tm Product length
β-actin CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 60 250 bp
P21 GAGGCCGGGATGAGTTGGGAGGAG CAGCCGGCGTTTGGAGTGGTAGAA 63 220 bp
P53 TAACAGTTCCTGCATGGGCGGC AGGACAGGCACAAACACGCACC 60 121 bp
P16 TTATTTGAGCTTTGGTTCTG CCGGCTTTCGTAGTTTTCAT 51 354 bp
XRCC4 AAGATGTCTCATTCAGACTTG CCGCTTATAAAGATCAGTCTC 54 233 bp
PTN GGAGCTGAGTGCAAGCAAAC GAGGTTTGGGCTTGGTCAGT 59 274 bp
MCM3 TCGAGGTAACCTTTGGTGGC TGTTCAGAAGCCTCGTCGTC 55 232 bp
CDKN2B CCCAACTCCACCAGATAGCA GGGATTTCCGCATCCTAGCA 57 198 bp
ERCC3 CCAGGAAGCGGCACTATGAGG GGTCGTCCTTCAGCGGCATTT 61 171 bp
Cmyc AAGACTCCAGCGCCTTCTCTC GTTTTCCAACTCCGGGATCTG 62 526 bp
VEGF-A GCAGAATCATCACGAAGTGG GCATGGTGATGTTGGACTCC 60 234 bp
TGF-β CAGATCCTGTCCAAGCTG TCGGAGCTCTGATGGTGTT 56 270 bp
Ang-1 GCTTACCAGATTCACACTGTTCC TTGCTACCTTGCCAACAACAACTG 60 612 bp
IL-6 CACAGACAGCCACTCACCTC TTTTCTGCCAGTGCCTCTTT 60 137 bp
HGF ATGCATCCAAGGTCAAGGAG TTCCATGTTCTTGTCCCACA 61 349 bp
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of chloroform and methanol at a ratio of 2:1 and the ab-
sorbance at 540 nm was measured against a blank solvent
using a spectrophotometer (SpectraMax M3, Molecular
Devices, Sunnyvale, CA, USA). Each sample was differenti-
ated, stained and quantified in duplicate. Osteogenic differ-
entiation was induced in confluent cultures of MSCs using
complete medium supplemented with 0.1 mM dexametha-
sone, 10 mM beta-glycerophosphate and 0.2 mM ascorbic
acid (all reagents from Sigma-Aldrich). After 18 days,
mineralization was detected by staining with Alizarin Red S
(Sigma-Aldrich). Mineralization was quantified by extraction
and measurement of Alizarin Red S uptake. The stained
sample was treated with 800 μl 10% acetic acid for 30 mi-
nutes on a shaker at room temperature. The cell layer was
then scraped, transferred into a 1.5 ml tube, heated at 85°C
for 10 minutes, cooled and centrifuged at 20,000 x g for
15 minutes. The supernatant was neutralized with 200 ml
10% v/v ammonium hydroxide and the absorbance at
405 nm was measured against the blank solvent, using a
plate reader (SpectraMax M3, Molecular Devices). Each
sample was differentiated, stained and quantified in dupli-
cate. Chondrogenic differentiation was brought about using
the StemPro Chondrogenesis Kit (Invitrogen; cat no.
A10071-01); subsequent sulfated glycosaminoglycan quantifi-
cation was carried out using the Blyscan Sulfated Glycosami-
noglycan Quantification Kit (Biocolor, Carrickfergus, County
Antrim, UK, Product Code: B3000), after normalizing DNA.
Enzyme-linked immunosorbent assay
Levels of angiogenic cytokines – vascular endothelial
growth factor (VEGF), transforming growth factor β-1
(TGF-β-1), hepatocyte growth factor (HGF) (R&DSystems, Minneapolis, USA) and angiopoietin 1 (Ray
Biotech, Norcross, GA, USA) were estimated using ELISA
kits, according to the manufacturers’ instructions. The sam-
ples were assayed in duplicate. In order to negate the possi-
bility of FBS contributing to the high level of cytokine
expression, we used human-specific ELISA kits. Also, the
respective complete media were used as controls.
Angiogenesis assay
Growth factor reduced Matrigel (Cat. No. 356231, BD
Biosciences, San Jose, CA, USA) was coated onto 48-
well plates and allowed to solidify at 37°C for 30 minutes.
Human umbilical vein endothelial cells (HUVEC, 2 ×
104) were suspended in the desired media condition to a
total volume of 250 μl and plated onto the GFR Matri-
gel. An anti-hHGF polyclonal neutralizing antibody
(Cat. No. ab10679, Abcam, Cambridge, England, UK)
was used for the blocking study. Plates were incubated
for six hours in 5% CO2 at 37°C. Images at a 4 X
magnification were taken using an inverted phase con-
trast microscope (Nikon). The mean tube length and the
mean number of branch points were analyzed using
WimTube software (Wimasis, GmbH, Munich, Germany)
from three random fields.
Imunosuppression and immunogenicity
For stimulation assays, MSCs treated with 10 μg/ml
mitomycin C (Sigma-Aldrich) for 2.5 hours were used as
stimulator cells, and allogeneic peripheral blood mono-
nuclear cells (PBMC) isolated by density gradient centri-
fugation were used as responder cells. MSCs were seeded
in 96-well plates (Corning, NY, USA) and allowed to at-
tach overnight. Responder PBMCs were then added to
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cultures were maintained for five days, at which
point they were pulsed with 5-bromo-2-deoxyuridine
(BrdU) for the final 24 hours. Cell proliferation was mea-
sured using a fluorimetric immunoassay kit (Calbiochem,
San Diego, CA, USA) for the quantification of BrdU
incorporation, according to the manufacturer’s instruc-
tions. One-way mixed lymphocyte reactions (MLR) at the
corresponding stimulator: responder ratio were used as
positive controls for PBMC proliferation in response to
alloantigen. For immunosuppression assays, mitomycin
C-treated MSCs were seeded in 96-well plates and
allowed to attach overnight. A one-way MLR at a ratio
of 1:2.5 was then added to each well. Lymphocyte
proliferation was measured at the end of five days, as
described above. A one-way MLR cultured in the ab-
sence of MSCs was considered as the 100% prolifera-
tion control. Four individual donors were analyzed in
each group. All treatments were performed in tripli-
cate wells in Roswell Park Memorial Institute (RPMI)
1640 medium (Invitrogen) supplemented with 10%
FBS (Hyclone), 2 mM glutamine (Invitrogen) and
0.05 mM beta-mercaptoethanol (Sigma-Aldrich).
Senescence, in vitro tumorigenecity and transformation
assays
In vitro tumorigenicity assay
We used a soft agar assay to assess the transformation
of MSCs in vitro. For this, cells at passage 5 were har-
vested, counted using a hemocytometer and resuspended
in growth media. The bottom layer of the soft agar plate
was made with 0.6% agarose, poured in a six multi-well
dish and allowed to settle for one hour at room tempe-
rature. The harvested cells were mixed with 0.3% aga-
rose at a concentration of 8,000 cells/well and were
overlaid above the bottom agar. The plates were pre-
incubated for 30 minutes at room temperature before
they were shifted to a CO2 incubator and were replen-
ished with fresh media at an interval of two to three
days. The formation of colonies was analyzed after 28 days
and, as a positive control, MCF-7 cells were cultured sim-
ultaneously. Colonies of sizes greater than 100 microns
under 10 X magnification were considered transformed.
Senescence assay
Cells grown in MesenCult XF SF media and DMEM
KO + 10% FBS culture conditions were comparatively
analyzed for the presence of senescent cells in culture, at
the end of passages 3 and 5. To do so, the cells were cul-
tured up to 60% confluence in 35 mm dishes and were
fixed and stained using a Senescence β-Galactosidase
Staining Kit (Cell Signaling Technology, Danvers, MA,
USA, cat.no. 9860), according to the manufacturer’s in-
structions. After an over-night incubation with thestaining solution, ten 10 X pictures per dish were
taken under the microscope. Senescent cells were
manually counted in each field. The assays were car-
ried out in duplicate.
Annexin V staining
We looked for the presence of apoptotic cells among
cultures in DMEM KO + 10% FBS and MesenCult, using
the Tali Apoptosis Kit – Annexin V Alexa Flour 488 and
propidium iodide (PI; cat no. 10788; Invitrogen), accor-
ding to the manufacturer’s instructions. After staining
the cells with Annexin V Alexa Flour 488 and PI, the
samples were loaded onto Tali Cellular Analysis Slides
(cat no. T10794; Invitrogen), following which 20 images
were captured using the Tali Image – Based Cytometer
(cat no. T10796; Invitrogen).
Cell cycle analysis
In order to analyze the percentage of cells in S phase at
passage 6, cells grown in DMEM KO + 10% FBS and in
MesenCult media were subjected to PI staining.
Passage 6 cultured cells were harvested, resuspended
in Dulbecco’s PBS (DPBS) (Invitrogen) and fixed using
70% ethanol. The cells were incubated for 15 minutes
on ice. They were then centrifuged and resuspended in
500 μL PI solution in DPBS (50 μg/mL PI), which also
contained 0.1 mg/ml RNase A and 0.05% Triton X-100.
The cells were incubated for 40 minutes at 37°C, after
which they were centrifuged and resuspended in DPBS
for flow analysis.
Karyotype analysis
To eliminate the possibility of chromosomal abnorma-
lities, karyotype analyses were carried out by making
metaphase spreads of cells cultured in DMEM KO + 10%
FBS and in MesenCult. The cultures were treated with
colchicine, following which they were harvested, briefly
treated with a hypotonic solution and fixed. The fixed
cells were then dropped on to a slide, dried and stained
to observe a G banding pattern.
Statistical analysis
Data are presented as mean ± SD. The statistical signifi-
cance was calculated using Student’s t test followed by
multiple comparison tests using Graph Pad Prism. P <0.05
was considered statistically significant.
Results
Media standardization for the isolation and expansion of
WJ-MSCs in xeno-free and serum-free conditions
We adapted the explant culture method for the isolation
of WJ-MSCs from the umbilical cord according to the
protocol mentioned in the Methods section, for two xeno-
free, serum-free media from two different vendors and
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culture conditions. The explant culture method allowed
us to reproducibly isolate WJ-MSCs from the umbilical
cords (n = 3) using StemPro XF, SFM and Mesencult XF,
SFM. WJ-MSCs isolated from the cords were expanded in
T25 or T75 flasks to passage 5 to study the growth kinet-
ics and surface marker expression profile. We observed a
significant difference in the morphology of the isolated
WJ-MSCs between xeno-free conditions and FBS contain-
ing medium. In the xeno-free culture, the cells exhibited
small, spindle shaped morphology whereas in the standardFigure 1 Growth kinetics and immunophenotype. A,B,C) Morphology p
passage 1; D,E,F) Pictures of WJ- MSCs grown in serum-containing and ser
population doublings obtained upon culturing WJ-MSCs in serum-containi
MSC positive and negative makers, expressed on WJ-MSCs cultured in threserum conditions, they showed a flattened fibroblast-like
morphology (Figure 1A-F). We were able to successfully
expand the cells from passage 0 to passage 5 for all three
cords in both Mesencult and DMEM KO +10% FBS,
whereas the StemPro XF SFM supported the growth of
only one cord until passage 5. The remaining two WJ-
MSC cultures did not propagate sufficiently beyond pas-
sage 2 and passage 4, respectively. At passage 5, total cell
yield for DMEM KO+ FBS, MesenCult XF,SFM and
StemPro XF,SFM were 9.7E + 08 ± 8.2E + 08, 3.7E + 10 ±
3.9E + 10, 5.1E + 08 ± 6.8E + 08 and cumulative populationictures of WJ-MSCs grown in serum-containing and serum-free media,
um-free media, passage 5; G,H) Total cell number and cumulative
ng and serum-free media, up to passage 5; I) Percentage expression of
e different media. WJ-MSCs, Wharton’s jelly-mesenchymal stem cells.
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spectively (Figure 1G,H).
Ex vivo expanded WJ-MSCs were immunophenotypi-
cally characterized by flow cytometry and the results are
presented in Figure 1I. With regard to the expression of
positive markers, such as CD73, CD105 and CD90, and
negative markers, such as CD34 and HLA-DR, we did
not observe a significant difference between the cells
grown in the three culture conditions.
Large scale expansion of WJ-MSCs using MesenCult XF,
SF medium
Due to the inconsistent results obtained using StemPro
XF, SF medium in isolating and expanding WJ-MSC in
our lab, upscaling studies were performed only with
Mesencult XF, SF medium (here onwards referred to as
XF, SFM). Before the large scale expansion, WJ-MSCs
were isolated from seven new cords in this medium, to
further validate the consistency of our isolation process.
WJ-MSCs isolated in Mesencult were expanded indi-
vidually to passage 5, in one cell stacks, to study theirFigure 2 Growth kinetics and CFU-F efficacy. A-F) Representative morp
and MesenCult XF,SF media; G,H,I) Total cell yield obtained at passage 5 u
K) Average number of colonies generated per 100 cells at passage 3 and p
J,L) Individual colonies captured at 4X magnification, for XF,SFM cultures a
GFU-F, colony-forming unit-fibroblast; MSCs, mesenchymal stem cells; WJ, Wgrowth kinetics. Morphological characteristics of these
cells expanded from passage 0 to passage 5 are given in
Additional file 1: Figure S1 (A-E). Mean population
doubling (PD) time and cumulative population dou-
blings (CPD) of WJ-MSCs in MesenCult medium were
28.8 ± 4.09 hours and 18.07 ± 1.21 hours, respectively.
We did not observe a significant difference in the ex-
pansion capability among the individual cords except
for one cord (designated as cord 7), where the average
doubling time went up to 37.11 hours (Additional file 1:
Figure S1). The CPD and total cell yield of the individ-
ual cords expanded in xeno-free medium from passage
0 to passage 5 are shown in Additional file 1: Figures S1:F
and S1:G. The results obtained from these studies clearly
suggest that the ex vivo growth of WJ-MSC, at least dur-
ing the early passages, is highly comparable between the
different cords tested.
Next, three individual cords were chosen for large
scale expansion in XF, SFM and were compared against
the same cells grown in serum containing medium. The
cells were isolated and expanded until passage 2 in Thology pictures of WJ derived MSCs cultured in DMEM KO + 10% FBS
sing XF,SF medium, compared against DMEM KO + 10% FBS;
assage 4, by cells cultured in XF,SF media and DMEM KO + 10% FBS;
nd DMEM KO + 10% FBS cultures, respectively. FBS, fetal bovine serum;
harton’s jelly.
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sage 2, the cells were seeded in a single cell stack for
large scale expansion and cultured up to passage 5. Cell
morphology was observed by phase contrast microscopy
and the results are shown in Figure 2A-F. We estimated
the total yield of WJ-MSCs at the end of passage 5
from all the cultures. The cumulative cell yield ranged
between 3.71E + 11 ± 1.2E + 11 for XF-SF medium and
5.21E + 09 ± 1.6E + 09 for DMEM KO + 10% FBS me-
dium (Figure 2G and I). The total cell yield from the XF,
SFM culture was significantly higher (P <0.003) than
that of the cells grown in DMEM KO + 10% FBS at all
the passages tested (passage 0 to passage 5) (Figure 2H).
The CPDs reached a peak of 18.32 ± 0.38 at the end of
passage 5 in XF, SFM as compared with 16.25 ± 0.26 in
DMEM KO + 10% FBS containing medium (P <0.02)
(Additional file 2: Figure S2: A). The mean population
doubling times of large scale expanded cells were ob-
served to be 32.13 ± 3.95 hours and 45.24 ± 4.35 hours
(P <0.01) for serum-free and serum-containing media,
respectively (Additional file 2: Figure S2: B). It is evident
from these results that cells cultured and expanded in
XF, SFM proliferate faster and the average yield is sig-
nificantly higher than those grown in serum containing
medium.
Clonogenic potential of WJ-MSCs
The colony forming unit-fibroblast (CFU-F) assay was
performed between the WJ-MSCs expanded in XF, SFM
and serum containing medium for passage 3 and Passage
4 (Figure 2J, K, and L). Cells expanded in MesenCult
had an average CFU-F of 23.33 ± 0.57 at passage 3 and
20 ± 1.0 at passage 4 whereas the cells expanded in the
DMEM KO + 10% FBS had 11 ± 1.5 at passage 3 and 13
± 3.08 at passage 4. The total number of colonies was
significantly higher with the cells expanded in XF, SFM
when compared to the cells in FBS containing medium
(P = 0.004). Surprisingly, unlike MesenCult grown cells,
we observed a difference in the number of CFU-Fs be-
tween the FBS grown cells at passage 3 and passage 4.
However, this increase was not found to be significant
(P = 0.3190).
Immunophenotypic analysis of WJ-MSC
The immunophenotypic profile was evaluated by examin-
ing the cell surface marker expression on the expanded
WJ-MSCs in both serum-free and serum-containing me-
dia at passage 3 and passage 5. A comprehensive panel of
positive and negative CD markers was used to characte-
rize the cells expanded in both conditions (Table 1). The
cells expanded in serum-free and serum-containing condi-
tions exhibited similar expression profiles for almost all
the markers tested, which is in accordance with the data
from previous studies [10], except for CD200, which is amember of the immunoglobulin super family and plays a
role in immune regulation [16] (Figure 3, Table 3). Thus,
the xeno-free serum-free medium used in this study did
not seem to have altered any of the commonly analyzed
MSC–associated markers when compared against stand-
ard conditions or culture duration.
Multilineage differentiation capacity
The multilineage differentiation capacity was evaluated
for WJ-MSCs expanded under both conditions along adi-
pogenic, osteogenic and chondrogenic lineages at passage
5 (Figure 4A-I). Adipogenic differentiation of the cells was
detected by staining of accumulated lipid vesicles using
Oil Red O stain. Uptake of the stain was then quantified
by spectrophotometric analysis. The data show that the
fold change above the undifferentiated control was similar
for the cells expanded under both conditions. The cells
expanded in Mesencult showed higher matrix minerali-
zation following osteo differentiation as confirmed by von
Kossa staining. Similarly, chondrocyte differentiation was
estimated by positive staining of sulfated glycosaminogly-
can (sGAG) after differentiation. Cellular sGAG content
was quantified and subsequently normalized to the DNA
content. Qualitative analysis did not reveal any significant
difference in the differentiation capacity of WJ-MSCs
expanded under both conditions, except for osteogenic
differentiation, where XF, SFM cells showed increased
in vitro osteogenic potential (Figure 4J,K and L).
Immunogenicity and immunosuppressive capacity
of WJ-MSC
The immunogenicity of WJ-MSC grown in XF-SF- and
FBS-containing media was tested in a one-way MLR
assay against allogeneic PBMCs and the results are pre-
sented in Figure 5A. Compared to allogeneic PBMCs,
both types of WJ-MSC population were significantly less
immunogenic at both passages 4 and 6. We then com-
pared the data between the two culture conditions. The
cells expanded in XF-SF medium were less immunogenic
compared to the cells grown in regular FBS medium;
however, the difference was not significant (P = 0.09).
Immunosuppressive capacity of the cells cultured in
both conditions was tested by comparing the ability to
suppress a two-way MLR. Lymphocyte proliferation was
strongly suppressed in the presence of WJ-MSCs iso-
lated and expanded in both conditions (Figure 5B). The
cells isolated and expanded in xeno-free medium were
found to have better immunosuppressive capacity when
compared to the standard FBS culture condition, al-
though it was not found to be significant (P = 0.0621).
Angiogenic potency of WJ-MSC
In order to evaluate the angiogenic potency, we cha-
racterized the secretome for angiogenic cytokines in the
Figure 3 Surface marker expression. A) Histograms showing percentage expression of MSC-positive markers; B) Histograms showing percentage
expression of MSC-negative markers. MSC, mesenchymal stem cells.
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serum-containing conditions. The levels of VEGF, Ang1,
HGF and TGF-beta1 were estimated by ELISA. The levels
of these cytokines in individual samples are provided in
Table 4. VEGF was completely absent in both culture con-
ditions whereas a measurable difference was noticed inthe secretion profile for the other cytokines between the
two conditions. The secretion profile was uniform in the
XF, SFM in comparison to the cells grown in the serum-
containing medium (Figure 6C, D and E). CM from XF,
SFM established cultures had uniform secretion of the an-
giogenic proteins and it correlated with gene expression
Table 3 Percentage expression of MSC-positive and negative markers, by cells cultured in MesenCult XFSM medium
and in DMEM KO + 10% FBS medium, at passages 3 and 5
KO + FBS P3 P5 XF,SFM P3 P5
CD markers Average ± SD Average ± SD CD Markers Average ± SD Average ± SD
CD 73 93.4 ± 1.7 85.9 ± 15.7 CD 73 94.3 ± 4.09 96.5 ± 0.68
CD 34 5.1 ± 2.3 4.2 ± 3.2 CD 34 3.3 ± 2.5 3.7 ± 1.04
CD 44 92.6 ± 1.4 85.9 ± 15.8 CD 44 95 ± 3 96.9 ± 2.7
CD 166 81.6 ± 8.2 84.7 ± 0.4 CD 166 82.2 ± 11.09 82 ± 2.7
CD 90 98.5 ± 0.6 95.9 ± 1.9 CD 90 98.2 ± 0.6 99.1 ± 0.7
CD 200 52 ± 7.5 46.2 ± 8.8 CD 200 13.5 ± 12.3 4.5 ± 5.6
CD 271 0.6 ± 0.2 0.33 ± 0.2 CD 271 2.2 ± 1.8 0.75 ± 0.2
CD 105 85.5 ± 5.5 71.5 ± 17.0 CD 105 97.7 ± 1.9 81.1 ± 7.2
HLA DR 0.7 ± 0.7 3 ± 2.1 HLA DR 2.9 ± 2.5 0.76 ± 0.73
CD 45 0.4 ± 0.5 4.4 ± 3.1 CD 45 0.23 ± 0.2 0.8 ± 0.7
CD 80 2.7 ± 0.4 0.13 ± 0.05 CD 80 2.6 ± 2.9 0.9 ± 0.8
HLA ABC 73 ± 16.9 41.4 ± 8.6 HLA ABC 81.06 ± 1.8 72.3 ± 23.6
MSC, mesenchymal stem cell; P, passage; SD, standard deviation.
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tional efficacy by the Matrigel tube formation assay using
HUVEC cells. HUVEC cells were plated on to the growth
factor reduced Matrigel with CM collected from the two
conditions. CM from both conditions was able to pro-
mote tube like structures within six hours. CM from XF,
SFM promoted longer tube structures and branch points
in comparison with serum-containing CM (Figure 6G-J’,
Additional file 3: Figure S3). As the cytokine analysis data
revealed that the HGF is significantly higher in XF, SFM
CM, we validated the role of HGF in an in vitro tube for-
mation assay using blocking anti HGF antibody. Upon
blocking HGF, we observed a significant reduction in the
tube length and branch points at six hours. Through these
results, we have clearly established that HGF is the main
factor responsible for the in vitro angiogenic proper-
ties contained within the CM from XF, SFM (Figure 6F
and G-J’).
Genomic stability, senescence and transformation marker
status and cell cycle analysis of expanded WJ-MSC in
xenofree culture
To determine the impact of large scale expansion of the
WJ-MSCs on the genomic stability, we subjected the
cells expanded in both conditions to karyotype analysis
on metaphasic WJ-MSCs at passage 5. The analysis re-
vealed no gross chromosomal aberrations, thus suggest-
ing that the cells preserved their normal karyotype in
both conditions (Figure 5C and D).
MSCs are also known to undergo replicative senescence
in vitro on extended passaging, which is characterized by
decreased proliferation, cell size enlargement, replicative
quiescence and an increase in senescence associated-β-gal
activity. We employed the enzyme lysosomal pH 6.0β-galactosidase as a senescence marker to obtain an
estimate of the percentage of senescent cells at pas-
sage 3 and passage 5, using serum-free and xeno-free
media. We observed considerable differences between
the WJ-MSCs grown in XF, SFM versus the cells that
were expanded in serum-containing medium at both
passage 3 and passage 5 (Figure 7A). While the per-
centage of senescent cells in XF, SFM remained 7.12 ±
2.82 (passage 3) and 1.53 ± 2.11 (passage 5), in serum-
containing medium the percentage of senescent cells pro-
gressively increased from 22.79 ± 0.77 (P3) to 30.22 ±
11.07 (passage 5) (Figure 7A). We also investigated the
apoptotic status of cells by Annexin V staining. The cells
cultured in XF, SFM showed a lower number of apoptotic
cells when compared to cells expanded in the standard
condition, although this difference was not significant
(P <0.12) (Figure 7B).
MSCs are known to adapt or acquire chromosomal
aberrations after extended passaging [17]. In order to en-
sure the safety of WJ-MSCs expanded in XF, SFM for
clinical use, we extensively characterized the cells and
subsequently looked at the in vitro tumorigenic potential
of these cells. Tumorigenic potential was assessed by soft
agar assay for colony formation to determine the trans-
formation status of the expanded cells. The cells were
cultured for almost a month and following the incuba-
tion period the number of colonies formed per well was
quantified. The cells isolated and expanded in both con-
ditions failed to form any colonies even after one month
of incubation. The human breast cancer cell line MCF-7
was used as the positive control and large colonies were
observed at the same seeding density (Figure 7C). We
also compared the gene expression of transformation- and
senescence-associated markers, such as P21, P53, P16,
Figure 4 Tri-lineage differentiation. A-I) Representative images of XF,SFM-cultured and DMEM KO + 10% FBS-cultured MSCs, differentiated into
adipocytes, osteocytes and chondrocytes, as visualized by Oil Red O, von Kossa and alcian blue stains, respectively, against undifferentiated con-
trols; J) Bar graph to quantify oil droplets, post Oil Red O staining; K) Bar graph to quantify mineralization, post alizarin red staining; L) Bar graph
to quantify sulfated glycosaminoglycan production by differentiated chondrocytes, normalized to DNA content. FBS, fetal bovine serum; MSCs,
mesenchymal stem cells.
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pression by RT-PCR of the cells cultured under both con-
ditions. The expression of P53, XRCC4, PTN, CDKN2B
and MCM3 was similar in cells cultured under both con-
ditions whereas with respect to P21, P16, ERCC3 and
cmyc we observed a difference in the expression levels
which was not significant (Figure 7D). These results
clearly suggest that the scaled up WJ-MSCs in the XF,
SFM condition did not exhibit potential for transform-
ation. Since the WJ-MSCs proliferated rapidly under the
XF, SFM condition, we examined the cell cycle status of
these cells. For identification of cell distribution during
the various phases of the cell cycle, we performed flow cy-
tometry analysis by staining the cells with PI. The cells
cultured in Mesencult had 19.8 ± 0.7% cells in S phasewhereas for the KO+ FBS cultures the value was 11.7 ±
4.7%. Similarly, for the G0/G1 phase the percentage of
cells in serum-free and serum-containing media was
68.6 ± 3.5 and 81.3 ± 4.9, respectively. In the G2 +M phase
the percentages were 1.3 ± 0.3 and 2.7 ± 0.5 for DMEM
KO+ FBS and XF, SFM cultures, respectively. These
results indicate that cells cultured in XF-SF medium
possessed higher proliferation capacity with the largest
proportion of cells found within the S phase (Figure 5D
and E).
Discussion
WJ-MSCs have gained significant attention in recent
years because of their similarity with MSCs obtained
from other sources as well as due to their ease of
Figure 5 Immunomodulation, karyotype and cell cycle analysis. A) Bar graph showing percentage suppression of PBMC-generated MLRs, by
cells cultured in XF,SF medium, against those cultured in DMEM KO + 10% FBS, at passages 4 and 6; B) Percentage proliferation brought about by
co-culturing MSCs (cultured in both conditions) with human peripheral blood-derived PBMCs, at passages 4 and 6, shown against a one-way
mixed lymphocyte reaction taken as 100% proliferation; C and D) Representative karyotypes of cells cultured in XF,SF medium and DMEM KO+ 10%
FBS, respectively, at passage 5; E) Percentage of cells cultured in XF,SFM and DMEM KO + 10% FBS, in S phase at passage 5; F) Percentage
of cells cultured in XF,SF medium and DMEM KO + 10% FBS in G0/G1, S and M phases, at passage 5. FBS, fetal bovine serum; PBMC,
peripheral blood mononuclear cells.
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display a majority of the properties of MSCs, such as
multipotency, higher proliferation rates, immunomodu-
latory properties and secretion of paracrine factors [18].
As a result, WJ-MSCs are believed to be potentially
ideal candidates for clinical applications for various
disease indications. However, in order to use these
cells in clinical settings, it is mandatory to establish aconsistently reproducible large scale production process
[19,20] and to define a standard operating procedure for a
good manufacturing practice (GMP)-compliant produc-
tion of MSCs [21], including selection of an optimal cell
therapy-compliant culture medium. We had earlier re-
ported that WJ-MSCs could be expanded to clinical scale
in reasonable time without altering their basic characteris-
tics [10]. Here we have extended our findings to report a
Table 4 Expression profile of pro-angiogenic cytokines, as observed in the secretome of cells cultured in MesenCult XF,
SFM and KO + FBS media
XF,SFM (ng/ml) KO + FBS (ng/ml)
Cytokines Cord 1 Cord 5 Cord 6 Cord 1 Cord 5 Cord 6
HGF 3.15 ± 0.49 2.8 ± 0.14 4.5 ± 0.7 40 ± 0.2 ND ND
TGF-β-1 0.24 ± 0.08 0.17 ± 0.01 0.27 ± 0.1 2.14 ± 0.02 1.9 ± 0.1 1.5 ± 0.07
Ang-1 3.85 ± 0.07 4.75 ± 0.07 4.62 ± 0.02 18.1 ± 0.5 48.25 ± 3.1 26.7 ± 2.1
VEGF ND ND ND ND ND ND
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process for the clinical scale expansion of WJ-MSCs. Most
current isolation and expansion procedures involve the
use of FBS as the main ingredient which does not have a
defined number of components and presents the risk of
transmission of unknown infectious agents. Thus, it has
become evident that culturing of MSCs in defined me-
dium that is FBS-free for large scale expansion of these
cells is critical for translational research [22]. In this
study, we tested two commercially available xeno-free
and serum-free media for the isolation and large scale ex-
pansion of WJ-MSC. Of the two media tested, Mesencult
XF, SFM was found to be best suited for the isolation and
expansion of WJ-MSC to a clinical scale in our hands.
Xeno-free serum-free established cultures of WJ-MSCs
were extensively characterized and compared with the
cells expanded using a standard FBS-containing medium.
We have adapted the explant culture technique instead of
the collagenase digestion method which was reported
earlier [23]. In addition, instead of porcine-derived trypsin,
a cell dissociation enzyme, TrypLE Select, free of any ani-
mal derived component, was used for dissociation of cul-
tured MSCs. Several groups have reported on the isolation
of MSCs from various tissue sources in xeno-free, serum-
free conditions in the recent past [24]. This is the first
report to demonstrate the isolation and large scale expan-
sion of WJ-MSCs in completely xeno-free and serum-free
conditions.
WJ-MSCs expanded in xeno-free, serum-free conditions
had significantly higher yield compared to FBS containing
medium. We had earlier optimized a protocol for scale-up
to 108 WJ-MSCs from a single umbilical cord within a
time period of 15 days [10]. Using the current xeno-free,
serum-free culture process, it took us approximately 13
days whereas for the DMEM KO +10% FBS, it took
15 days to arrive at the specified cell number.
In order to meet with clinical translational require-
ments, we further analyzed the post-freeze thaw viability
and characteristics of the cells cultured in both condi-
tions. MesenCult XF, SFM cultured cells were frozen in
a commercially available serum-free cryopreservation so-
lution, containing 10% dimethylsulfoxide (DMSO), while
DMEM KO + FBS cultured cells were frozen in thetraditional FBS + 10% DMSO mix. Upon thawing the
cells frozen at passage 5, we observed that the cell viabil-
ity was between 92% and 100% for both conditions (data
not shown).
Furthermore, culturing the cells under the XF-SF con-
dition did not result in significant variation of their
typical MSC marker expression profile. However, we no-
ticed changes in the expression of CD200 levels between
the two culture conditions used. Generally, MSCs ex-
pressing CD200 are known to suppress TNF α produc-
tion by CD200 receptor positive macrophages. Among
the different MSC sources, WJ-MSCs express CD200 in
a higher proportion and they have been reported to play
an important role in regulating immune responses [16].
Cells expanded in xeno-free and serum-free medium
contain a lower percentage of CD200 positive cells. Al-
though the expanded cells expressed a lower percentage
of CD200 positive cells, these WJ-MSCs exhibited higher
immunosuppression activity in the MLR assay when com-
pared to the cells expanded in FBS-containing media.
Since immunosuppression activity is a multifactorial pro-
cess, the exact mechanism through which the Mesencult
grown cells render immunosuppression remains to be de-
termined. The cells cultured under both conditions were
negative for HLA-DR and the co-stimulatory molecules
CD40, CD80 and CD86, which could potentially induce T
cell anergy tolerance and explain the immune privileged
status of MSCs [25,26]. In addition, there are several other
factors that have been proposed to play a critical role in
regulating the immunosuppressive effects of MSCs, in-
cluding HLA-G, nitric oxide, indoleamine 2,3-dioxygenase
(IDO), HGF, TGFβ and so on.
Multilineage differentiation potential, which is the hall-
mark of these MSCs, was not compromised by the xeno-
free, serum-free culture conditions. It has been reported
that WJ-MSCs have lower adipo and chondro differenti-
ation potential when compared to bone marrow and other
sources of MSCs. We observed that the xeno-free and
serum-free cultures have lower adipo and more osteo and
chondro differentiation potential when compared with
serum-containing cultures. Our results corroborated the
earlier report which has demonstrated robust osteogenic
differentiation with the xeno-free and serum-free
Figure 6 Angiogenic potency. A, B) Real-time PCR quantification of HGF, VEGF, TGFβ-1 and IL6 for cells cultured in DMEM KO + 10% FBS and in
XF,SFM, all normalized against Cord 1 (DMEM KO + 10% FBS); C,D,E) Box graphs representing variations observed between cells cultured in XF,
SFM and FBS-containing medium, when analyzed for cytokine secretions of TGFβ, HGF and Ang1; F) Tube formation efficiency (estimated using
HUVEC, cultured on growth factor reduced Matrigel) of WJ-MSC-conditioned medium, from three cords cultured in DMEM KO + 10% FBS and in
XF, SFM. Anti-HGF neutralizing antibody was used to block tube formation in each condition. G-J’) Representative 4 X pictures showing tubes formed.
FBS, fetal bovine serum; HGF, hepatocyte growth factor; TGFβ1, transforming growth factor-β1; VEGF, vascular endothelial growth factor. ** signifies
extent of significance of the numeric value.
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Figure 7 Senescence, apoptosis and transformation. A) Percentage of senescent cells in XF,SFM cultures, compared against DMEM KO + 10%
FBS cultures at P5 followed by representative 10 X images of fields showing blue colored senescent cells; B) Percentage of Annexin positive
(apoptotic) cells in XF,SFM cultures compared to DMEM KO + 10% FBS cultures at P5 followed by representative images of fields showing green
colored apoptotic cells; C) Representative pictures of cells cultured in soft agar medium, showing no colonies in XF,SFM and DMEM KO + 10%
FBS cultures, compared to colonies observed in MCF-7 cultures; D) Comparative gene expression analysis between cells cultured in XF,SF medium
and DMEM KO + 10% FBS at P6. FBS, fetal bovine serum; P, passage.
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by the CFU-F assay unequivocally demonstrated the
superiority of the cells expanded under xeno-free, serum-
free conditions.
The proposed mechanisms of action of MSCs are be-
lieved to occur primarily through their paracrine activity
[27]. We observed that the cells grown under XF-SF
conditions displayed a more consistent pattern of angio-
genic factors secretion compared to the FBS grown cells.The secretion profile also correlated with the gene ex-
pression data shown in Figure 6. When the functional
activity of the angiogenic factors was assessed in vitro,
we observed that the CM derived from XF SF cultures
showed increased neo angiogenesis. These results cor-
roborated well with earlier reports published by Corotchi
et al. and Choi et al., using WJ-MSCs [15,28].
It is known that long-term culture of primary cells
might also have therapeutic consequences, although this
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[21]. Furthermore, there is a growing perception that
even under highly standardized culture conditions, the
probability that continuous culturing of cells may even-
tually lead to replicative senescence is a hypothesis that
further warrants experimental investigation [29,30]. Al-
though there are no specific molecular markers to track
the cellular aging in MSCs, we have addressed the replica-
tive senescence issue by examining senescence associated-
β-gal activity in our cell populations. In the XF, SFM
condition we were not able to detect a significant number
of senescent WJ-MSCs, and similarly very few apoptotic
cells were observed in our cultures. To further analyze the
senescence-associated marker profile in these cells we
measured the expression of several cell cycle associ-
ated genes. For the most part, the expression profile
was similar between the two cell types except for a
few genes whose function has been attributed to cell
proliferation and DNA repair [29]. Proliferation under
non-physiologic in vitro culture conditions could result in
mutations and chromosomal aberrations. Conventional
karyotype analysis of the cells in both conditions has not
revealed any major genomic gains or losses and we did
not observe cells with transforming potential in our cul-
ture conditions.
Based on the results reported here, Mesencult XF, SFM
appears to be a suitable medium of choice for the large
scale expansion of WJ-MSCs, without compromising the
quality of these cells. We observed that Mesencult medium
supported the growth and expansion of WJ-MSCs that
could be taken forward for clinical application. Alternatives
to FBS, such as human AB serum or platelet lysates, can-
not be considered as a better choice for producing MSCs
for clinical use since the regular availability of consistent
reagents may be difficult. Although the successful isolation
of MSCs has been performed with serum and in the ab-
sence of it, for most serum-free, xeno-free commercially
available solutions, effective cell isolation remains challen-
ging [31]. Initial cell adhesion in xeno-free and serum-free
cultures still remains a major problem since most commer-
cial serum-free media require precoating of culture vessels,
which makes it difficult for large scale expansion in cell
stacks. However, in this study we have successfully demon-
strated the feasibility and optimization of isolation and
large scale expansion of WJ-MSC more efficiently and con-
sistently, in the large numbers required to meet the clinical
demand. Based on the data presented in this report, we be-
lieve that these cells could be therapeutically effective in
preclinical and clinical evaluation.
Conclusions
In summary, safety is the first objective to meet in cellu-
lar therapy and this warrants the production of safe stem
cell products and requires extensive quality monitoringto ensure that the cells maintain overall phenotype and
functional potential and exhibit normal genotype. We
have systematically developed a large scale production
process, using completely xeno-free, serum-free medium.
Extensive characterization revealed that the WJ-MSCs
that are expanded in Mesencult xeno-free, serum-free me-
dium consistently exhibit greater angiogenic potential
when compared to those expanded under standard serum
containing conditions.
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